Merck & Co., Inc. completed a public offering of $5 billion in various debt securities, including Floating Rate Notes and other fixed-rate notes, with maturities ranging from 2027 to 2055. The offering included $500 million of Floating Rate Notes, $750 million of 3.850% Notes due 2027, $750 million of 4.150% Notes due 2030, $1 billion of 4.550% Notes due 2032, $1.75 billion of 4.950% Notes due 2035, and $1.25 billion of 5.700% Notes due 2055.
The debt securities were issued under an existing indenture and are part of the company's strategy to manage its capital structure. The legal and procedural documentation related to the offering has been filed with the Securities and Exchange Commission, ensuring compliance with regulatory requirements.
linkSep 09, 2025 16:33:09
Merck & Co. reported its financial results for the second quarter of 2025, with GAAP earnings per share (EPS) at $1.76, a decrease from $2.14 in the same quarter of 2024. The company recorded a gross margin of 77.5%, up from 76.8% year-over-year, largely due to a favorable product mix. Research and development expenses increased by 16% to $4.0 billion, influenced by a $200 million upfront payment for a license agreement with Jiangsu Hengrui Pharmaceuticals. Non-GAAP EPS was $2.13, down from $2.28, reflecting higher operating expenses and unfavorable foreign exchange impacts. Additionally, Merck announced a planned acquisition of Verona Pharma for approximately $10 billion, expected to close in Q4 2025, which adds to its cardio-pulmonary pipeline.
As part of a new multiyear optimization initiative, Merck approved a restructuring program aimed at generating $3.0 billion in annual cost savings by the end of 2027. This program will involve eliminating certain administrative, sales, and research positions while continuing to hire in strategic growth areas. The anticipated pretax costs for the restructuring are estimated at $3.0 billion, with approximately 60% expected to be cash-related. The initiative is designed to redirect resources toward new product launches and enhance the company's pipeline across various therapeutic areas.
linkJul 29, 2025 06:42:43
Merck announced its financial results for the first quarter of 2025, reporting a GAAP earnings per share (EPS) of $2.01 and a non-GAAP EPS of $2.22. The increase in EPS compared to the first quarter of 2024 was primarily due to a previous charge related to the acquisition of Harpoon Therapeutics. The company noted a gross margin of 78.0%, an increase from the previous year, attributed to product mix and lower restructuring costs, despite higher amortization and foreign exchange impacts. Research and development expenses decreased by 9% year-over-year, largely due to a significant charge in the prior year, although new costs were incurred for milestone achievements and increased clinical development activities.
In addition to financial results, Merck highlighted advancements in its pipeline, including key regulatory milestones for several products in oncology and vaccines. Notable developments include the submission of applications for subcutaneous pembrolizumab and the initiation of a Phase 3 trial for an investigational treatment for diffuse large B-cell lymphoma. The company also received various approvals for its vaccines in Europe and China. Merck plans to invest significantly in U.S. manufacturing and R&D, with over $12 billion allocated since 2018 and expectations for additional investment by 2028. The company updated its full-year 2025 sales outlook to between $64.1 billion and $65.6 billion, factoring in the impact of tariffs and foreign exchange.
linkApr 24, 2025 06:45:16
Merck reported a 7% increase in pharmaceutical sales for 2024, reaching $57.4 billion, driven by strong demand for products like KEYTRUDA and the successful launch of WINREVAIR. The company's gross margin improved to 76.3% for the year, aided by a favorable product mix and foreign exchange effects. Additionally, Merck's non-GAAP earnings per share rose significantly to $7.65, compared to $1.51 in 2023, reflecting operational strength and reduced charges from business development activities.
However, Merck faced challenges with lower sales in certain areas, including JANUVIA and LAGEVRIO, primarily due to pricing pressures and generic competition. The company also reported a decline in research and development expenses, down 41% for the full year, which could impact future innovation. Furthermore, the effective tax rates were influenced by reductions in reserves for unrecognized income tax benefits, which may not be sustainable in the long term.
linkFeb 04, 2025 06:45:47
Merck has announced the election of Surendralal L. Karsanbhai to its board of directors, effective January 1, 2025. Karsanbhai, currently the CEO of Emerson Electric Co., brings extensive business experience and a global perspective to the board, which will now consist of 13 members. His background includes various leadership roles at Emerson since 1995 and positions on other influential boards, including the Federal Reserve Bank of St. Louis.
While the addition of Karsanbhai is seen as a positive move for Merck, the company also faces ongoing challenges in the pharmaceutical industry, including regulatory pressures and competition. The press release does not provide specific financial metrics or performance indicators, but it highlights Merck's commitment to research and innovation in health solutions, emphasizing its long history and aspirations in the biopharmaceutical sector.
linkNov 22, 2024 14:28:06
Merck's third-quarter financial results for 2024 showed total worldwide sales of $16.7 billion, marking a 4% increase from the previous year. The growth was driven by increased usage of KEYTRUDA, new product launches like WINREVAIR and CAPVAXIVE, and a strong performance in the Animal Health sector. The company reported a gross margin improvement to 75.5% and a net income attributable to Merck of $1.24 per share, although this was affected by a net charge related to acquisitions. Non-GAAP earnings per share (EPS) also saw a decline to $1.57, down from $2.13 in the same quarter last year due to similar acquisition-related charges and restructuring costs.
On the downside, Merck experienced lower sales in certain products, including JANUVIA, JANUMET, and GARDASIL/GARDASIL 9, particularly due to reduced demand in China. Additionally, the company faced a significant increase in research and development (R&D) expenses, which rose by 77% compared to the prior year, primarily due to acquisition costs. Despite these challenges, Merck continues to expand its pipeline and has achieved several regulatory milestones, indicating ongoing progress in its strategic initiatives.
linkOct 31, 2024 06:44:02
Merck's second-quarter results for 2024 show positive growth, with total sales increasing by 7% to $16.1 billion. Key product KEYTRUDA experienced a 16% sales rise, driven by higher demand in various cancer treatments. The company launched WINREVAIR, contributing to overall success. However, some products like JANUVIA saw significant declines due to competition and lower demand. Overall, Merck's strong momentum reflects effective execution and innovation in addressing medical needs.
linkJul 30, 2024 06:41:50
Merck's Q1 2024 results show a 9% increase in sales, with notable growth in oncology and vaccines. Key products like KEYTRUDA and GARDASIL/GARDASIL 9 saw significant sales increases. The company received FDA approval for WINREVAIR and expanded its pipeline through acquisitions. Merck raised its 2024 sales and EPS outlook. Despite declines in certain products like JANUVIA/JANUMET, overall performance was positive, with a focus on innovation and strategic development.
linkApr 25, 2024 06:41:15
Merck reported a 6% increase in fourth-quarter sales, reaching $14.6 billion, and a 1% increase in full-year sales, reaching $60.1 billion. Key products like KEYTRUDA and GARDASIL/GARDASIL 9 saw strong sales growth, while LAGEVRIO sales declined. The company achieved FDA approvals, initiated multiple phase 3 studies, and augmented its pipeline through acquisitions and collaborations. Merck also provided a positive financial outlook for 2024 with anticipated sales between $62.7 billion and $64.2 billion and non-GAAP EPS between $8.44 and $8.59.
linkFeb 01, 2024 06:39:01
Merck announced its third-quarter 2023 financial results, reporting a 7% increase in total worldwide sales, with sustained growth in oncology and vaccines. Key highlights include the growth of KEYTRUDA sales by 17% to $6.3 billion, the collaboration agreement with Daiichi Sankyo for three clinical-stage ADC candidates, and the FDA approval of KEYTRUDA for perioperative treatment of certain patients with NSCLC. Merck also provided its full-year 2023 financial outlook, raising and narrowing its expected worldwide sales range and adjusting its non-GAAP EPS to reflect the negative impact of foreign exchange and upfront charges related to the collaboration agreement with Daiichi Sankyo.
linkOct 26, 2023 06:38:04